An operational rejig at DPT Laboratories, an expansion at UDG, and a synthesis and toxicology testing contract win for Dalton – welcome to Outsourcing-Pharma’s CDMO round-up.
Ambit Biosciences has entered into a discovery and development
collaboration with pharmaceutical company Cephalon, signifying the
first time a pharma company has decided to characterise their
entire library of potential drugs based...
The next generation of anti-cancer drugs took a positive step
forward after scientists successfully inhibited an enzyme that is
responsible for catalysing uncontrolled and abnormal cell
divisions.
Tool supplier, EMD Biosciences has released the first comprehensive
guide to inhibitors for signal transduction and drug discovery
research that will enable researchers to pinpoint specific enzymes
as a possible target for drug therapy.
TransTech Pharma and Merck has announced a $26 million research
collaboration using TransTech's proprietary TTP Translational
Technology to discover and develop novel small molecules for a
therapeutic target of interest to Merck.
Genentech's strategy of expanding beyond its traditional territory
of protein-based drugs and into small molecules has been reinforced
by a new agreement with Array BioPharma.
Two $500m-plus licensing deals reveal the rewards available to
biotech firms with novel drugs, but also the lengths large
biopharma companies will now go to secure exclusive rights to
promising candidates, even if they are in the...
US Pharmacopeia has entered into a research collaboration focused
on inflammation with Celgene Corporation. The companies will work
together to identify promising small molecule lead compounds
suitable for further development.
